Informations générales (source: ClinicalTrials.gov)
Epidemiological, Clinical and Biological Characteristics and Therapeutic Management of ICU Patients With Severe Acute Exacerbation of COPD. Evaluation of the Prognosis and the Factors Associated With Survival Multicentre Prospective Observational Register
Observational [Patient Registry]
Versailles Hospital (Voir sur ClinicalTrials)
novembre 2022
décembre 2027
16 septembre 2025
COPD is one of the leading causes of morbidity, mortality and health care utilisation
worldwide. Currently, COPD is the third leading cause of death worldwide and is therefore
a major public health problem. Projections show an increase in the prevalence and burden
of COPD in the coming decades due to ageing populations and continued exposure to risk
factors.
In patients with COPD, mortality due to exacerbations is about 35%. Exacerbations
represent the most important respiratory event in the history of this chronic disease and
are of major socio-economic interest (about 50-75% of healthcare expenditure in this
disease).
In the most severe cases, COPD exacerbations lead to respiratory distress with
hypercapnic ventilatory acidosis requiring ventilatory support. These most severe
episodes are common, accounting for 20% of exacerbations and are a signal of advanced
disease, with a high risk of future hospitalisations and a limited long-term prognosis.
Despite progress in management, the mortality of these severe acute exacerbations is
around 15% in the ICU and 20% in hospital. The long-term prognosis following
hospitalisation for an acute exacerbation of COPD is poor with a 5-year mortality of
around 50%. On the one hand, the means and treatments likely to improve the prognosis of
these patients are of great medical and socio-economic interest, on the other hand, it
seems important to identify the elements that may be associated with management failure
and to treat them where appropriate.
Thus, improving scientific knowledge thanks to prospective data, evaluating the different
characteristics and prognosis of patients hospitalised for a severe acute exacerbation of
COPD seems, in the 21st century, a major axis in order to continue to optimise the
individual management of these patients but also collectively, given the COPD public
health burden.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CH DE VERSAILLES SITE ANDRE MIGNOT | Alexis Ferré, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Age ≥ 40 years old
2. COPD documented or strongly suspected
- Chronic respiratory symptoms (dyspnoea, cough and/or sputum)
- Exposure to a known risk factor for COPD (such as tobacco smoke)
- If available, respiratory function tests showing non- or partially reversible
obstructive syndrome (post-bronchodilator ratio FEV1/CV < 0.7)
3. Severe acute exacerbation, defined as a worsening of the patient's usual respiratory
symptoms with signs of acute respiratory distress (polypnoea ≥ 30 cycles.min-1 or
use of accessory respiratory muscles) and/or hypercapnic acidosis (with PaCO2 ≥ 45
mmHg and pH ≤ 7.35)
4. Admission to an ICU, or a dedicated respiratory intensive care unit
1. Age ≥ 40 years old
2. COPD documented or strongly suspected
- Chronic respiratory symptoms (dyspnoea, cough and/or sputum)
- Exposure to a known risk factor for COPD (such as tobacco smoke)
- If available, respiratory function tests showing non- or partially reversible
obstructive syndrome (post-bronchodilator ratio FEV1/CV < 0.7)
3. Severe acute exacerbation, defined as a worsening of the patient's usual respiratory
symptoms with signs of acute respiratory distress (polypnoea ≥ 30 cycles.min-1 or
use of accessory respiratory muscles) and/or hypercapnic acidosis (with PaCO2 ≥ 45
mmHg and pH ≤ 7.35)
4. Admission to an ICU, or a dedicated respiratory intensive care unit
1. Known asthma (according to the criteria of the international "Global Initiative for
Asthma" guidelines)
2. Patient refusal to participate (information note, application for non-opposition)